

D-NOME to develop technology for anti-microbial resistance (AMR) detection

07 February 2023 | News

Recently announced seed funding of \$1.5 million



D-NOME, a synthetic biology startup based in Hyderabad, is on a mission to democratise molecular diagnostics with the world's first deviceless PCR technology, enabling precision & personalised medicine at scale.

Although their primary focus is on respiratory infections, the startup is currently developing a technology for the detection of anti-microbial resistance (AMR).

Founded in 2021 by scientists turned entrepreneurs, Dr Divya Sriram and Dr Sujoy Deb, who combined their experience in molecular diagnostics and next-gen genome sequencing to build rapid, accurate and point-of-care diagnostics for human infectious diseases and other applications.

They have recently announced their Seed Round of \$1.5 million led by Ankur Capital and joined by other investors- Campus Fund, 8X Ventures, 3iPartners/Impact Fund and Seeders (LV angel fund).

The startup has also raised pre-seed funding from Entrepreneur First and received the national BIG-BIRAC grant (IKP-Hyderabad), Nidhi-Prayas Grant (AIC-Banasthali) and were winners of the Hello Tomorrow Global Deep Tech Challenge 2021. They are incubated at Atal Incubation Centre-CCMB and were recently part of Rebalance Accelerator Cohort 04.

"D-NOME's unique cost-effective platform technology will curb the spread of infectious diseases across a range of industry applications. The team at D-NOME has the right mix of science, engineering and product leadership to transform the diagnostics market as a whole. We're excited to partner with them at this early stage of the journey to unlock immense value from India to the world", said Ritu Verma, Managing Partner & Co-founder, Ankur Capital.

D-NOME's loop mediated isothermal amplification technology (LAMP) is a low cost alternative to PCR technology. It has already been tested on numerous clinical samples across strains of COVID-19 with high accuracy. The recent fundraise aims to accelerate the clinical trials and scale up for deployment. The technology has the power to rapidly screen not only multiple infectious diseases with high accuracy but also can be expanded to screening of non-communicable diseases.